A Study to Test How Iclepertin is Taken up in the Blood of People With and Without Liver Problems
Status:
Not yet recruiting
Trial end date:
2023-07-28
Target enrollment:
Participant gender:
Summary
This study is open to people with and without liver problems. People can join the study if
they are 18 to 79 years of age and have a body mass index (BMI) between 18.5 and 35 kg/m2.
Iclepertin (also called BI 425809) is a medicine that is being developed to treat diseases of
the brain. The purpose of this study is to find out whether having liver problems influences
how iclepertin is taken up in the body. All participants take iclepertin once as a tablet.
Participants are in the study for 2 to 3 weeks. During the first part of the study, they stay
at the study site for 4 nights. Afterwards, there are 5 visits to the study site and 1 call.
The site staff measures the amount of iclepertin in the blood. The doctors also regularly
check participants' health and take note of any unwanted effects.